✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Avaclyr is a drug marketed by Fera Pharms Llc and is included in one NDA.
The generic ingredient in AVACLYR is acyclovir. There are fifty-six drug master file entries for this compound. Sixty-two suppliers are listed for this compound. Additional details are available on the acyclovir profile page.
A generic version of AVACLYR was approved as acyclovir by TEVA on April 22nd, 1997.
AVACLYR is protected by zero US patents and one FDA Regulatory Exclusivity.
FDA Regulatory Exclusivity protecting AVACLYR
INDICATED FOR THE TREATMENT OF ACUTE HERPETIC KERATITIS (DENDRITIC ULCERS) IN PATIENTS WITH HERPES SIMPLEX (HSV-1 AND HSV-2) VIRUS
Exclusivity Expiration: See Plans and Pricing
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|Fera Pharms Llc||AVACLYR||acyclovir||OINTMENT;OPHTHALMIC||202408-001||Mar 29, 2019||DISCN||Yes||No||See Plans and Pricing||See Plans and Pricing||See Plans and Pricing|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>TE||>Type||>RLD||>RS||>Patent No.||>Patent Expiration||>Product||>Substance||>Delist Req.||>Exclusivity Expiration|